Loading...

We've got a brand new version of Simply Wall St! Try it out

Medlab Clinical

ASX:MDC
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MDC
ASX
A$78M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

Medlab Clinical Limited engages in the sale of nutraceutical products, and pharmaceutical research and commercialization in Australia. The last earnings update was 80 days ago. More info.


Add to Portfolio Compare Print
  • Medlab Clinical has significant price volatility in the past 3 months.
MDC Share Price and Events
7 Day Returns
-5.1%
ASX:MDC
4.7%
AU Biotechs
0.9%
AU Market
1 Year Returns
-6.3%
ASX:MDC
50.9%
AU Biotechs
16.3%
AU Market
MDC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Medlab Clinical (MDC) -5.1% -14.9% -26% -6.3% -50% -
AU Biotechs 4.7% 8.7% 20% 50.9% 168.8% 226.4%
AU Market 0.9% 1.9% 5.1% 16.3% 22.3% 22.5%
1 Year Return vs Industry and Market
  • MDC underperformed the Biotechs industry which returned 50.9% over the past year.
  • MDC underperformed the Market in Australia which returned 16.3% over the past year.
Price Volatility
MDC
Industry
5yr Volatility vs Market

MDC Value

 Is Medlab Clinical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Medlab Clinical. This is due to cash flow or dividend data being unavailable. The share price is A$0.37.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Medlab Clinical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Medlab Clinical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:MDC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in AUD A$-0.04
ASX:MDC Share Price ** ASX (2019-11-17) in AUD A$0.37
Global Biotechs Industry PE Ratio Median Figure of 145 Publicly-Listed Biotechs Companies 30.8x
Australia Market PE Ratio Median Figure of 519 Publicly-Listed Companies 18.63x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Medlab Clinical.

ASX:MDC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:MDC Share Price ÷ EPS (both in AUD)

= 0.37 ÷ -0.04

-9.56x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Medlab Clinical is loss making, we can't compare its value to the Global Biotechs industry average.
  • Medlab Clinical is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Medlab Clinical's expected growth come at a high price?
Raw Data
ASX:MDC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -9.56x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Global Biotechs Industry PEG Ratio Median Figure of 85 Publicly-Listed Biotechs Companies 1.39x
Australia Market PEG Ratio Median Figure of 347 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Medlab Clinical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Medlab Clinical's assets?
Raw Data
ASX:MDC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in AUD A$0.07
ASX:MDC Share Price * ASX (2019-11-17) in AUD A$0.37
Australia Biotechs Industry PB Ratio Median Figure of 38 Publicly-Listed Biotechs Companies 3.17x
Australia Market PB Ratio Median Figure of 1,584 Publicly-Listed Companies 1.75x
ASX:MDC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:MDC Share Price ÷ Book Value per Share (both in AUD)

= 0.37 ÷ 0.07

5.19x

* Primary Listing of Medlab Clinical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Medlab Clinical is overvalued based on assets compared to the AU Biotechs industry average.
X
Value checks
We assess Medlab Clinical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Medlab Clinical has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

MDC Future Performance

 How is Medlab Clinical expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Medlab Clinical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Medlab Clinical expected to grow at an attractive rate?
  • Unable to compare Medlab Clinical's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Medlab Clinical's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare Medlab Clinical's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:MDC Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 13%
Australia Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 10.3%
Australia Market Earnings Growth Rate Market Cap Weighted Average 9.7%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:MDC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:MDC Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
ASX:MDC Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2019-06-30 5 -10 -8
2019-03-31 5 -9 -7
2018-12-31 6 -7 -6
2018-09-30 6 -6 -5
2018-06-30 4 -5 -5
2018-03-31 4 -5 -4
2017-12-31 5 -5 -4
2017-09-30 5 -4 -4
2017-06-30 4 -4 -4
2017-03-31 4 -4 -4
2016-12-31 4 -4 -4
2016-09-30 3 -4 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Medlab Clinical is high growth as no earnings estimate data is available.
  • Unable to determine if Medlab Clinical is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:MDC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Medlab Clinical Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:MDC Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
ASX:MDC Past Financials Data
Date (Data in AUD Millions) EPS *
2019-06-30 -0.04
2019-03-31 -0.03
2018-12-31 -0.03
2018-09-30 -0.03
2018-06-30 -0.02
2018-03-31 -0.02
2017-12-31 -0.02
2017-09-30 -0.02
2017-06-30 -0.02
2017-03-31 -0.02
2016-12-31 -0.02
2016-09-30 -0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Medlab Clinical will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Medlab Clinical's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Medlab Clinical's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Medlab Clinical's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Medlab Clinical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Medlab Clinical has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

MDC Past Performance

  How has Medlab Clinical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Medlab Clinical's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Medlab Clinical does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Medlab Clinical's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Medlab Clinical's 1-year growth to the Global Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Medlab Clinical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Medlab Clinical Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:MDC Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 5.43 -8.09 9.50
2019-03-31 5.11 -7.03 8.48
2018-12-31 6.19 -5.97 7.31
2018-09-30 5.87 -5.27 6.63
2018-06-30 4.14 -4.57 6.10
2018-03-31 4.45 -4.40 5.84
2017-12-31 4.76 -4.22 5.58
2017-09-30 4.60 -3.94 5.30
2017-06-30 4.45 -3.66 5.02
2017-03-31 4.02 -3.59 4.67
2016-12-31 3.59 -3.52 4.31
2016-09-30 3.10 -3.50 4.09
2016-06-30 2.62 -3.49 3.87
2015-06-30 1.09 -3.05 3.16
2014-12-31 0.09 -2.42 2.20

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Medlab Clinical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Medlab Clinical has efficiently used its assets last year compared to the Global Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Medlab Clinical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Medlab Clinical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Medlab Clinical has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

MDC Health

 How is Medlab Clinical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Medlab Clinical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Medlab Clinical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Medlab Clinical's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Medlab Clinical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 19.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Medlab Clinical Company Filings, last reported 4 months ago.

ASX:MDC Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 14.99 0.97 11.44
2019-03-31 14.99 0.97 11.44
2018-12-31 18.09 0.16 16.12
2018-09-30 18.09 0.16 16.12
2018-06-30 21.86 0.50 20.33
2018-03-31 21.86 0.50 20.33
2017-12-31 1.47 0.64 0.79
2017-09-30 1.47 0.64 0.79
2017-06-30 3.05 0.30 1.50
2017-03-31 3.05 0.30 1.50
2016-12-31 5.09 0.33 4.31
2016-09-30 5.09 0.33 4.31
2016-06-30 1.89 0.27 0.80
2015-06-30 0.26 1.00 0.12
2014-12-31 2.36 0.24 1.08
  • Medlab Clinical's level of debt (6.5%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Medlab Clinical's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Medlab Clinical has sufficient cash runway for 1.1 years based on current free cash flow.
  • Medlab Clinical has less than a year of cash runway if free cash flow continues to grow at historical rates of 34.1% each year.
X
Financial health checks
We assess Medlab Clinical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Medlab Clinical has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

MDC Dividends

 What is Medlab Clinical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Medlab Clinical dividends.
If you bought A$2,000 of Medlab Clinical shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Medlab Clinical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Medlab Clinical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:MDC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 59 Stocks 2.1%
Australia Market Average Dividend Yield Market Cap Weighted Average of 390 Stocks 4%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.4%
Australia Top 25% Dividend Yield 75th Percentile 5.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:MDC Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Medlab Clinical has not reported any payouts.
  • Unable to verify if Medlab Clinical's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Medlab Clinical's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Medlab Clinical has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Medlab Clinical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Medlab Clinical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Medlab Clinical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

MDC Management

 What is the CEO of Medlab Clinical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Sean Hall
COMPENSATION A$327,739
CEO Bio

Dr. Sean Michael Hall serves as the Chief Executive Officer and Managing Director of Medlab Clinical Limited. Dr. Hall started Medlab in August 2012. Dr. Hall has over 20 years of experience in the Australian Healthcare and food industries (nutraceutical sales and development) and early phase drug discovery in Australia and Asia. Dr. Hall was one of the founders of FIT-BioCeuticals LTD (www.fit-bioceuticals.com.au) and through his management and guidance, BioCeuticals (leading brand) expanded into a leadership role in the Australian Health Care community. His focus on leadership and innovation has led to the authoring of multiple patents, written peer reviewed articles and lectures at scientific conferences. Dr. Hall has been a Director of Medlab Clinical Limited since April 17, 2014. Dr. Hall serves as a Board Member of the International Probiotics Association (IPA). Dr. Hall is an active member of Medicines Australia, American Federation for Medical Research (AFMR), American Academy of Anti-Aging Medicine (A4M), AusBiotech and a member of the Scientific Advisory Board for BITs Life Science China. Dr. Hall has co-authored a number of peer-reviewed industry papers, lectured at scientific events and developed many patented products. Dr. Hall is the 2012 Finalist Australian Growth Company Awards, CEO Exit of the Year for his trade sale to Blackmores. Dr. Hall has completed Executive Education at Harvard Graduate School of Business. He holds B.A(Psych), MBA and MD.

CEO Compensation
  • Sean's compensation has increased whilst company is loss making.
  • Sean's remuneration is about average for companies of similar size in Australia.
Management Team

Sean Hall

TITLE
MD, CEO & Director
COMPENSATION
A$328K

Alan Dworkin

TITLE
CFO & Company Secretary
COMPENSATION
A$268K
TENURE
4.8 yrs

Luis Vitetta

TITLE
Director of Medical Research
COMPENSATION
A$274K

David Rutolo

TITLE
Director of Science
COMPENSATION
A$181K

Paul Vilner

TITLE
Director of Commercial Operations
COMPENSATION
A$359K
TENURE
1.4 yrs
Board of Directors

Michael Hall

TITLE
Non-Executive Chairman
COMPENSATION
A$130K

Sean Hall

TITLE
MD, CEO & Director
COMPENSATION
A$328K
TENURE
5.6 yrs

Drew Townsend

TITLE
Non-Executive Director
COMPENSATION
A$60K
AGE
54
TENURE
5.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
04. Jun 19 Sell Michael Hall Individual 30. May 19 30. May 19 -38,355 A$0.41 A$-15,629
24. May 19 Sell Michael Hall Individual 23. May 19 23. May 19 -30,000 A$0.41 A$-12,340
24. May 19 Buy Drew Townsend Individual 24. May 19 24. May 19 80,000 A$0.20 A$16,000
X
Management checks
We assess Medlab Clinical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Medlab Clinical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

MDC News

Simply Wall St News

Medlab Clinical (ASX:MDC) May Be Weighed Down By Its Debt

We can see that Medlab Clinical Limited (ASX:MDC) does use debt in its business. … The image below, which you can click on for greater detail, shows that Medlab Clinical had debt of AU$158.4k at the end of December 2018, a reduction from AU$635.2k over a year. … ASX:MDC Historical Debt, July 26th 2019 A Look At Medlab Clinical's Liabilities Zooming in on the latest balance sheet data, we can see that Medlab Clinical had liabilities of AU$1.99m due within 12 months and liabilities of AU$143.9k due beyond that.

Simply Wall St -

Could Medlab Clinical Limited's (ASX:MDC) Investor Composition Influence The Stock Price?

As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.' Medlab Clinical is a smaller company with a market capitalization of AU$79m, so it may still be flying under the radar of many institutional investors. … Insider Ownership Of Medlab Clinical While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. … Private Company Ownership It seems that Private Companies own 16%, of the MDC stock.

Simply Wall St -

Did You Miss Medlab Clinical's (ASX:MDC) 61% Share Price Gain?

For example, Medlab Clinical Limited (ASX:MDC) shareholders have seen the share price rise 61% over three years, well in excess of the market return (17%, not including dividends). … We'd be remiss not to mention the difference between Medlab Clinical's total shareholder return (TSR) and its share price return. … We note that Medlab Clinical's TSR, at 66% is higher than its share price return of 61%

Simply Wall St -

Do Insiders Own Lots Of Shares In Medlab Clinical Limited (ASX:MDC)?

If you want to know who really controls Medlab Clinical Limited (ASX:MDC), then you'll have to look at the makeup of its share registry. … Medlab Clinical is a smaller company with a market capitalization of AU$81m, so it may still be flying under the radar of many institutional investors. … Our analysis of the ownership of the company, below, shows that.

Simply Wall St -

A Holistic Look At Medlab Clinical Limited (ASX:MDC)

Attractive stocks have exceptional fundamentals. … In the case of Medlab Clinical Limited (ASX:MDC), there's

Simply Wall St -

How Much Of Medlab Clinical Limited (ASX:MDC) Do Insiders Own?

The big shareholder groups in Medlab Clinical Limited (ASX:MDC) have power over the company. … With a market capitalization of AU$90m, Medlab Clinical is a small cap stock, so it might not be well known by many institutional investors. … View our latest analysis for Medlab Clinical

Simply Wall St -

Interested In Medlab Clinical Limited (ASX:MDC)? Here's How It Performed Recently

When Medlab Clinical Limited (ASX:MDC) released its most recent earnings update (31 December 2017), I wanted to understand how these figures stacked up against its past performance. … The two benchmarks I used were Medlab Clinical's average earnings over the past couple of years, and its industry performance. … ASX:MDC Income Statement May 12th 18 We can further analyze Medlab Clinical's loss by looking at what the industry has been experiencing over the past few years.

Simply Wall St -

Who Owns Medlab Clinical Limited (ASX:MDC)?

View our latest analysis for Medlab Clinical ASX:MDC Ownership_summary Mar 31st 18 Institutional Ownership In MDC's case, institutional ownership stands at 10.50%, significant enough to cause considerable price moves in the case of large institutional transactions, especially when there is a low level of public shares available on the market to trade. … This level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and potential acquisitions. … As a result, potential investors should further explore the company's business relations with these companies and find out if they can affect shareholder returns in the long-term.Next Steps: The company's high institutional ownership makes margin of safety a very important consideration to existing investors since long bull and bear trends often emerge when these big-ticket investors see a change in long-term potential of the company.

Simply Wall St -

Medlab Clinical Limited's (ASX:MDC) Profit Outlook

They expect the company to post a final loss in 2019, before turning a profit of AU$6.80M in 2020. … Working backwards from analyst estimates, it turns out that they expect the company to grow 92.53% year-on-year, on average, which is extremely buoyant. … Next Steps: There are too many aspects of MDC to cover in one brief article, but the key fundamentals for the company can all be found in one place – MDC’s company page on Simply Wall St.

Simply Wall St -

What Is The Future Prospect For Healthcare And Medlab Clinical Limited (ASX:MDC)?

See our latest analysis for Medlab Clinical What’s the catalyst for Medlab Clinical's sector growth? … Medlab Clinical lags the pack with its lower growth rate of 5.04% over the past year, which indicates the company will be growing at a slower pace than its biotech peers. … If Medlab Clinical has been on your watchlist for a while, now may be the time to enter into the stock, if you like its growth prospects and are not highly concentrated in the biotech industry.

Simply Wall St -

MDC Company Info

Description

Medlab Clinical Limited engages in the sale of nutraceutical products, and pharmaceutical research and commercialization in Australia. The company develops bio-therapeutics for bio-therapeutics for chronic kidney diseases, pre-diabetes/obesity, depression, and musculoskeletal muscle loss associated with ageing. It also provides nutraceuticals for anti-inflammatory, cardiovascular support, endocrine support, gastrointestinal support, immunological support, infants and toddlers, metabolic support, musculoskeletal support, neurological support, sports performance, urogenital support, and weight management, as well as for men, pregnancy, seniors, teenagers, and women support. Medlab Clinical Limited was founded in 2012 and is based in Alexandria, Australia.

Details
Name: Medlab Clinical Limited
MDC
Exchange: ASX
Founded: 2012
A$78,078,016
211,021,667
Website: http://www.medlab.co
Address: Medlab Clinical Limited
66 McCauley Street,
Alexandria,
New South Wales, 2015,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX MDC Ordinary Shares Australian Securities Exchange AU AUD 14. Jul 2015
OTCPK MDBB.F Ordinary Shares Pink Sheets LLC US USD 14. Jul 2015
CHIA MDC Ordinary Shares Chi-X Australia AU AUD 14. Jul 2015
Number of employees
Current staff
Staff numbers
0
Medlab Clinical employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 10:44
End of day share price update: 2019/11/17 00:00
Last estimates confirmation: 2018/08/31
Last earnings filing: 2019/08/30
Last earnings reported: 2019/06/30
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.